These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27884224)

  • 1. The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome.
    Cabandugama PK; Gardner MJ; Sowers JR
    Med Clin North Am; 2017 Jan; 101(1):129-137. PubMed ID: 27884224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
    Sowers JR; Whaley-Connell A; Epstein M
    Ann Intern Med; 2009 Jun; 150(11):776-83. PubMed ID: 19487712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
    Ruiz-Hurtado G; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Aldosterone in Obesity-Related Hypertension.
    Kawarazaki W; Fujita T
    Am J Hypertens; 2016 Apr; 29(4):415-23. PubMed ID: 26927805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity, kidney dysfunction and hypertension: mechanistic links.
    Hall JE; do Carmo JM; da Silva AA; Wang Z; Hall ME
    Nat Rev Nephrol; 2019 Jun; 15(6):367-385. PubMed ID: 31015582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity, kidney dysfunction, and inflammation: interactions in hypertension.
    Hall JE; Mouton AJ; da Silva AA; Omoto ACM; Wang Z; Li X; do Carmo JM
    Cardiovasc Res; 2021 Jul; 117(8):1859-1876. PubMed ID: 33258945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
    Hall JE; do Carmo JM; da Silva AA; Wang Z; Hall ME
    Circ Res; 2015 Mar; 116(6):991-1006. PubMed ID: 25767285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.
    Aroor AR; McKarns S; Demarco VG; Jia G; Sowers JR
    Metabolism; 2013 Nov; 62(11):1543-52. PubMed ID: 23932846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Renal Oxidative Stress in the Pathogenesis of the Cardiorenal Syndrome.
    Giam B; Kaye DM; Rajapakse NW
    Heart Lung Circ; 2016 Aug; 25(8):874-80. PubMed ID: 27132623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep apnea, aldosterone, and resistant hypertension.
    Pimenta E; Calhoun DA; Oparil S
    Prog Cardiovasc Dis; 2009; 51(5):371-80. PubMed ID: 19249443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial.
    Dorresteijn JA; Schrover IM; Visseren FL; Scheffer PG; Oey PL; Danser AH; Spiering W
    J Hypertens; 2013 Feb; 31(2):393-403. PubMed ID: 23235355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic options in patients prone to hypertension: a focus on direct Renin inhibition and aldosterone blockade.
    Basile J
    Am J Med Sci; 2009 Jun; 337(6):438-44. PubMed ID: 19390429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiorenal Syndrome Revisited.
    Zannad F; Rossignol P
    Circulation; 2018 Aug; 138(9):929-944. PubMed ID: 30354446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M; Fujita T
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress in the cardiorenal metabolic syndrome.
    Whaley-Connell A; Sowers JR
    Curr Hypertens Rep; 2012 Aug; 14(4):360-5. PubMed ID: 22581415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension.
    Schütten MT; Houben AJ; de Leeuw PW; Stehouwer CD
    Physiology (Bethesda); 2017 May; 32(3):197-209. PubMed ID: 28404736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and insulin resistance in resistant hypertension: implications for the kidney.
    Rao A; Pandya V; Whaley-Connell A
    Adv Chronic Kidney Dis; 2015 May; 22(3):211-7. PubMed ID: 25908470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug mechanisms to help in managing resistant hypertension in obesity.
    Jansen PM; Danser JA; Spiering W; van den Meiracker AH
    Curr Hypertens Rep; 2010 Aug; 12(4):220-5. PubMed ID: 20532698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.